NCT04224428

Role of Fexofenadine in Diabetic Kidney Disease

Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

* This study will that will be conducted on 60 outpatients previously diagnosed with type 2 diabetes mellitus. * Patients will be recruited from Internal Medicine Department, Tanta University Hospital, Tanta, Egypt. This study will be randomized, controlled, parallel, prospective clinical study. Accepted patients will be randomized into 2 groups as the following * Group 1 (Control group): 30 patients will receive maximum tolerated dose of ACEI for six months * Group 2 (Fexofenadine group): 30 patients will receive maximum tolerated dose of ACEI plus fexofenadine tablets 60 mg once daily for six months The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) after six months of treatment

Conditions

• Diabetic Kidney Disease

Interventions

Type	Name	Description
DRUG	Fexofenadine Pill	fexofenadine tablets 60 mg once daily will be taken for six months
DRUG	Placebo oral tablet	lactose oral tablet

Timeline

• Start date: 2020-01-01
• Primary completion: 2022-02-01
• Completion: 2022-02-01
• First posted: 2020-01-13
• Last updated: 2022-05-05

Locations

1 site across 1 country: Egypt